Synonyms :

Transmembrane activator and CAML interactor, TNFRSF13B

Description :

TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI binds to both APRIL and BAFF and can stimulate the activation of transcription factors; NF-kappaB, AP-1, and mediates calcineurin dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor. Recombinant human TACI is a soluble 160 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous cysteine rich extracellular domain of the TACI protein.

Catalog #:

310-17

Source :

E.coli

Stability :

The lyophilized protein is stable for at least 2 years from date of receipt at -20⁰C. Reconstituted TACI is stable for at least 3 months when stored in working aliquots with a carrier protein at -20⁰C. Avoid repeated freeze/thaw cycles.

Purity :

Greater than 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin Level :

Endotoxin level is less than 0.1 ng per µg (1EU/µg).

Biological Activity :

Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 µg/ml.

AA Sequence :

MSGLGRSRRG GRSRVDQEER FPQGLWTGVA MRSCPEEQYW DPLLGTCMSC KTICNHQSQR TCAAFCRSLS CRKEQGKFYD HLLRDCISCA SICGQHPKQC AYFCENKLRS PVNLPPELRR QRSGEVENNS DNSGRYQGLE HRGSEASPAL PGLKLSADQV

PubMed Link :

TACI+AND+human

Country of Origin :

USA